The Drug Enforcement Administration this week proposed reducing aggregate production quotas for five opioid controlled substances in 2020. The proposal would reduce the amounts of fentanyl by 31%, hydrocodone by 19%, hydromorphone by 25%, oxycodone by 9% and oxymorphone by 55%. The five opioid substances were subject to special scrutiny following the enactment last year of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, which requires DEA to estimate the amount of diversion of the covered substance that occurs in the United States and make appropriate quota reductions. DEA will accept comments on the 2020 proposed aggregate production quotas, which address more than 250 Schedule I and II controlled substances, through Oct. 15.

Related News Articles

Headline
Physicians registered with the Drug Enforcement Administration will no longer need to meet the X-waiver requirement to prescribe treatments such as…
Blog
The opioid epidemic impacts all racial and ethnic groups, but attention paid to this epidemic has often neglected to include Black/African American communities…
Headline
Sejal B. Shah, M.D., and Carla B. Monteiro, a licensed clinical social worker, at Boston-based Brigham and Women’s Hospital write that stigma and disparities…
#HealthCareInnovation Thursday Blog
During the COVID-19 pandemic, opioid overdoses have skyrocketed — doubling in some places from just one year ago. Physical isolation, disruption in regular…
Headline
Combating stigma is the missing element to the nation’s response to the addiction crisis, writes Matthew Stefanko, director of National Stigma Initiative for…
Headline
In this first in a series of AHA blogs about reducing stigma, Richard Bottner, a physician assistant and affiliate faculty member at Dell Medical School at the…